(Total Views: 488)
Posted On: 06/25/2021 11:57:38 AM
Post# of 36563
Youhou,
Good catch. Thanks. At least GNBT will get a little cash back from NGIO.
The table below sets forth the manner in which we expect to use the net proceeds we receive from this offering. All amounts included in the table below are estimates.
Description Amount
Covid Vaccine Research & Development $1,925,000
Ii-Key Vaccine Manufacturing $2,974,500
Covid Vaccine Clinical Trials $20,325,589
Payable to Generex for R&D and Manufacturing costs for the Covid Vaccine $4,500,000
AE37 Clinical Trials $11,681,523
Operations $3,545,542
G&A $887,850
Net proceeds $45,840,004
The foregoing information is an estimate based on our current business plan. We may find it necessary or advisable to re-allocate portions of the net proceeds reserved for one category to another, and we will have broad discretion in doing so. Pending these uses, we intend to invest the net proceeds of this offering in a money market or other interest-bearing account.
https://www.sec.gov/Archives/edgar/data/18045...rms1a2.htm
Good catch. Thanks. At least GNBT will get a little cash back from NGIO.
The table below sets forth the manner in which we expect to use the net proceeds we receive from this offering. All amounts included in the table below are estimates.
Description Amount
Covid Vaccine Research & Development $1,925,000
Ii-Key Vaccine Manufacturing $2,974,500
Covid Vaccine Clinical Trials $20,325,589
Payable to Generex for R&D and Manufacturing costs for the Covid Vaccine $4,500,000
AE37 Clinical Trials $11,681,523
Operations $3,545,542
G&A $887,850
Net proceeds $45,840,004
The foregoing information is an estimate based on our current business plan. We may find it necessary or advisable to re-allocate portions of the net proceeds reserved for one category to another, and we will have broad discretion in doing so. Pending these uses, we intend to invest the net proceeds of this offering in a money market or other interest-bearing account.
https://www.sec.gov/Archives/edgar/data/18045...rms1a2.htm
(5)
(0)
